Satish Eraly

Satish Eraly, MD, PhD, currently serves as Senior Medical Director at Alnylam Pharmaceuticals, leading the clinical development of the vutrisiran program and the HELIOS-B trial for TTR amyloidosis. Previous roles include Medical Director at Biogen, where leadership spanned ALS clinical development and multiple investigational therapies, and Associate Medical Director focusing on pediatric MS and early ALS therapies. At the University of California, San Diego, Eraly was Principal Investigator and Associate Professor, directing a multidisciplinary research program and publishing extensively, including on predictive biomarkers for PTSD. With a background as an attending physician and post-doctoral fellow, Eraly holds a Master's in Clinical Research, an MD from UCSD School of Medicine, and a PhD in Molecular Biology.